2-hydroxy-2,2-diphenyl-N-<(1,2,3,6-tetrahydro-4-pyridyl)methyl>acetamide | 153196-03-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxy-2,2-diphenyl-N-<(1,2,3,6-tetrahydro-4-pyridyl)methyl>acetamide
• 英文别名: 2-hydroxy-2,2-diphenyl-N-(1,2,3,6-tetrahydropyridin-4-ylmethyl)acetamide
• CAS: 153196-03-3
• 化学式: C₂₀H₂₂N₂O₂
• 分子量: 322.407
• InChiKey: SPBDVVIMTYKMSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  61.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  丙酮 、 2-hydroxy-2,2-diphenyl-N-<(1,2,3,6-tetrahydro-4-pyridyl)methyl>acetamide 在 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 反应 96.0h， 生成 2-hydroxy-2,2-diphenyl-N-<(1,2,3,6-tetrahydro-1-isopropyl-4-pyridyl)methyl>acetamide
  参考文献：
  名称：

  用于治疗逼尿肌过多的药物。VI。N取代基中带有环胺的乙酰胺衍生物的合成和药理特性。

  摘要：

  为了提高功效并减少奥昔布宁（1）的副作用，N-[（四氢-3-或4-吡啶基）甲基]-，N-（4-哌啶基）-和N-（3合成了-或4-哌啶基烷基）-2-羟基乙酰胺（3a-n​​，4a-g）和相关的羧酰胺（3o-r，4h-k，13'，17）并评估了其对膀胱节律性收缩的抑制活性大鼠和散瞳活动的大鼠。这些化合物中的一些在对膀胱收缩的抑制活性和对膀胱收缩的抑制活性与散瞳活性之间的选择性方面均优于奥昔布宁。其中，N-[（（1,2,3,6-四氢-4-吡啶基）甲基]-和N-[（1,2,3,6-四氢-1-甲基-4-吡啶基）甲基]- 2-羟基-2,2-二苯基乙酰胺（3e，3f）对膀胱收缩表现出最有效的抑制活性（ED30 = 0。静脉注射分别为005和0.003 mg / kg）。从3e对豚鼠体外逼尿肌收缩的影响来看，似乎3e体内抑制膀胱收缩的活性主要与卡巴胆碱诱导的体外对逼尿肌收缩的抑制活性有关（类抗毒蕈碱活性）。

  DOI：

  10.1248/cpb.42.74
• 作为产物：
  描述：

  4-乙酰氨基甲基吡啶 在 sodium hydroxide 、 sodium tetrahydroborate 、 氢溴酸 、 N,N'-羰基二咪唑 作用下， 以 甲醇 、 二氯甲烷 、 溶剂黄146 、 1,2-二氯乙烷 、 丙酮 为溶剂， 反应 48.25h， 生成 2-hydroxy-2,2-diphenyl-N-<(1,2,3,6-tetrahydro-4-pyridyl)methyl>acetamide
  参考文献：
  名称：

  用于治疗逼尿肌过多的药物。VI。N取代基中带有环胺的乙酰胺衍生物的合成和药理特性。

  摘要：

  为了提高功效并减少奥昔布宁（1）的副作用，N-[（四氢-3-或4-吡啶基）甲基]-，N-（4-哌啶基）-和N-（3合成了-或4-哌啶基烷基）-2-羟基乙酰胺（3a-n​​，4a-g）和相关的羧酰胺（3o-r，4h-k，13'，17）并评估了其对膀胱节律性收缩的抑制活性大鼠和散瞳活动的大鼠。这些化合物中的一些在对膀胱收缩的抑制活性和对膀胱收缩的抑制活性与散瞳活性之间的选择性方面均优于奥昔布宁。其中，N-[（（1,2,3,6-四氢-4-吡啶基）甲基]-和N-[（1,2,3,6-四氢-1-甲基-4-吡啶基）甲基]- 2-羟基-2,2-二苯基乙酰胺（3e，3f）对膀胱收缩表现出最有效的抑制活性（ED30 = 0。静脉注射分别为005和0.003 mg / kg）。从3e对豚鼠体外逼尿肌收缩的影响来看，似乎3e体内抑制膀胱收缩的活性主要与卡巴胆碱诱导的体外对逼尿肌收缩的抑制活性有关（类抗毒蕈碱活性）。

  DOI：

  10.1248/cpb.42.74

文献信息

• METHODS FOR TREATING RESPIRATORY DISORDERS
  申请人：Nitromed, Inc.

  公开号：EP1942909A2

  公开（公告）日：2008-07-16
• 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS
  申请人：Antibe Therapeutics Inc.

  公开号：EP2041108A1

  公开（公告）日：2009-04-01
• Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
  申请人：Ellis James L.

  公开号：US20090018091A1

  公开（公告）日：2009-01-15

  The invention describes compositions and kits comprising at least one nitric oxide enhancing group antimicrobial compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The antimicrobial compounds of the invention are preferably tobramycin, aztreonam, ciprofloxacin and doripenam. The nitric oxide enhancing antimicrobial compounds are substituted with at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. In one embodiment the methods of the invention are for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating Bacillus anthracis infections.
• Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
  申请人：Ellis James L.

  公开号：US20090042819A1

  公开（公告）日：2009-02-12

  The invention describes novel organic nitric oxide donor salts of a antimicrobial compounds, and novel compositions and kits comprising at least one organic nitric oxide donor salt of an antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. In one embodiment the antimicrobial compounds of the invention are aztreonam, ciprofloxacin, doripenam, duramycin and tobramycin. The organic nitric oxide donors that form salts are preferably organic nitrates, organic nitrites, nitrosothiols, thionitrites and heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are preferably furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. The methods of the invention are preferably for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating Bacillus anthracis infections.
• Nitrosated and/or nitrosylated compounds, compositions and methods of use
  申请人：Ellis James L.

  公开号：US20090131342A1

  公开（公告）日：2009-05-21

  The invention describes novel nitrosated and/or nitrosylated compounds of the invention and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the invention, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one compound of the invention, and at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The nitrosated and/or nitrosylated compounds of the invention are preferably nitrosated and/or nitrosylated antimicrobial compounds, nitrosated and/or nitrosylated adenosine antagonists, nitrosated and/or nitrosylated LTB4 antagonists, nitrosated and/or nitrosylated mucoregulators and nitrosated and/or nitrosylated purine agonists. The methods of the invention are preferably for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis.